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Introduction
Rheumatoid arthritis (RA) is a common autoimmune 
disease characterized by chronic inﬂ   ammation of the 
joints, which can ultimately lead to cartilage and bone 
destruction. In the past decade it has become apparent 
that citrullinated proteins/peptides, and in particular 
auto  antibodies directed to them (anti-citrullinated 
protein antibodies (ACPA)), are likely to be involved in 
the development of this disease in at least 70% of the 
patients (reviewed in [1]). In the clinical setting, ACPA 
have mostly been detected using the anti-cyclic citrul-
linated peptide (anti-CCP) test, although more recently 
other tests using various citrullinated proteins have also 
been employed.
Recently it became clear that RA patients can be 
classiﬁ  ed into two major subsets; namely, those who have 
ACPA (anti-CCP(+)) and those who do not (anti-CCP(–)) 
[2]. Whilst in the early phase of the disease these two 
groups of patients show a very similar clinical 
presentation, the picture changes considerably as the 
disease develops further. Th   e presence of ACPA at early 
diagnosis predicts more pronounced radiographic pro-
gres  sion, as demonstrated by many studies showing a 
strong association between anti-CCP positivity and the 
development of bone erosions. Importantly, environ-
mental risk factors (for exam  ple, tobacco smoking) diﬀ  er 
to a large extent between these two populations [3], and 
the risk of developing ischemic heart disease is clearly 
higher in anti-CCP(+) patients compared with anti-
CCP(–) RA patients [4]. Furthermore, treatment 
response to, for example, synthetic disease-modifying 
antirheumatic drugs such as methotrexate may diﬀ  er 
between these groups of patients [5]. It is therefore 
important for a clinician to be able to accurately separate 
anti-CCP(+) patients from anti-CCP(–) patients. During 
such a decision-making process it is important that both 
clinicians and laboratory specialists are fully aware of the 
advantages and disadvantages of the various ACPA tests 
that are commercially available.
Th  e present review intends to critically review the 
literature on comparisons between the most frequently 
applied commercial tests in terms of speciﬁ  city  and 
sensitivity of ACPA detection.
Anti-citrullinated protein antibodies and cyclic 
citrullinated peptide
Several lines of evidence indicate that the ACPA response 
in RA patients is polyclonal and heterogeneous [6]. Anti-
bodies to a variety of citrullinated epitopes on diﬀ  erent 
proteins can thus be detected and their production is 
likely to vary between individual patients. Th  e  commer-
cial ACPA tests are all aimed at detecting most, if not all, 
ACPA epitope reactivities found in RA patients. Th  e 
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ACPA in RA patients was investigated have used the 
second-generation CCP test (termed the CCP2 test). 
Using this CCP2 test, about 75% of RA patients with a 
long-term established diagnosis and 61% of patients with 
established early RA were anti-CCP(+) (Table 1).
Anti-CCP antibodies of these patients can be eluted 
from the CCP2 ELISA plate (by low pH or high salt) and 
the eluate can subsequently be used to stain western blots 
containing diﬀ   erent citrullinated proteins, such as 
ﬁ  brino  gen, histones or vimentin. Th  e eluted antibodies 
react with all of these citrullinated proteins, indicating 
broad cross-reactivity between anti-CCP and these various 
antigens (R Toes, personal communication). Th  ese data 
have been complemented by studies of syno  vial exosomes 
from RA patients, which were shown to contain ACPA as 
well as a number of citrullinated con  stituents – for 
example, citrullinated ﬁ   brinogen peptides and citrul  li-
nated Spα (a CD5 antigen-like protein) [7]. Moreover, the 
number of anti-CCP(–) sera that show reactivity with 
other citrullinated antigens is very small [8,9]. Taken 
together, these data indicate that the vast majority of 
ACPA can be detected by the CCP2 test.
Anti-CCP(+) RA and anti-CCP(–) RA
Early diagnosis of RA coupled with rational use of 
disease-modifying antirheumatic drugs has been shown 
to have a favorable eﬀ  ect on the course of the disease. 
Early and accurate diagnosis has therefore become 
increasingly important. For several reasons, the presence 
of anti-CCP antibodies is a great help to clinicians in 
deciding which patient needs early treatment.
First, anti-CCP antibodies are very speciﬁ  c for RA, and 
they are produced at signiﬁ   cant levels very early in 
disease. Th  e speciﬁ  city of anti-CCP antibodies for the 
diagnosis of RA is high, as shown in Table 1. In addition, 
it is known that anti-CCP antibodies can be present 
many years before the ﬁ   rst visit to the clinic (up to 
18 years) [10-12].
Second, studies of early arthritis cohorts have shown 
that a large number of these early arthritis patients 
cannot be accurately diagnosed at their ﬁ  rst visit, and 
hence are often referred as undiﬀ  erentiated  arthritis 
patients. If patients are found to be anti-CCP(+) when 
referred to the clinician, however, more than 90% develop 
RA within 3 years – in contrast to only 30% of the anti-
CCP(–) patients. Th   e presence of anti-CCP antibodies in 
undiﬀ   erentiated arthritis therefore accurately predicts 
development of RA [13,14].
Th   ird, the presence of anti-CCP antibodies at the ﬁ  rst 
visit to the clinician predicts radiographic progression, as 
demonstrated by many studies that have shown a strong 
association of anti-CCP positivity with the development 
of bone erosions [1,15,16]. In the past, IgM rheumatoid 
factor (RF) positivity was assumed to predict radio-
graphic progression, but a recent report clearly indicates 
that the radiographic progression seen is actually asso-
ciated with ACPA(+)/RF(+) and ACPA(+)/RF(–) RA, but 
not with ACPA(–)/RF(+) and ACPA(–)/RF(–) RA [17]. 
Th   e conclusion therefore seems to be that the presence of 
ACPA as such is associated with an erosive course and 
the presence of IgM RF is just a co-expressed auto-
antibody, as has been known for a long time.
Fourth, more germinal centers in synovial tissue inﬁ  l-
trates are found in anti-CCP(+) RA patients [18]. It is 
known that germinal centers contribute to RA patho-
genesis by supporting autoantibody production [19]. In 
the same report, distinct synovial features such as 
increased ﬁ   brosis in the synovial tissue and a thicker 
synovial lining layer were found in anti-CCP(–) RA 
patients [18].
In conclusion, although at baseline the clinical features 
of both RA subsets are very similar, anti-CCP(+) RA is 
more strongly associated with poor outcome than anti-
CCP(–) RA (reviewed in [20]).
Th   is conclusion may also have important implications 
for treatment. Synthetic disease-modifying antirheumatic 
drugs, such as methotrexate, are often used in treating 
RA, frequently in combination with TNFα blockers to 
enhance the treatment response. In a large Dutch study – 
the so-called PROMPT study (methotrexate versus 
placebo treatment) – Van Dongen and coworkers found 
that anti-CCP(+) patients responded well to methotrexate 
treatment, while a parallel anti-CCP(–) patient group did 
not [5]. In a subsequent study it was shown that metho-
trexate treatment resulted in a more favorable response 
in patients with a low or intermediate pretreatment level 
of ACPA [21]. Th  ese data not only suggest that the 
eﬀ  ectiveness of a drug can be diﬀ  erent in anti-CCP(+) as 
compared with anti-CCP(–) arthritis, but also that very 
early treatment, even in patients not yet fulﬁ  lling 
American College of Rheumatology (ACR) criteria for 
RA, can be beneﬁ  cial if used in a selective way [20].
Table 1. Sensitivity and specifi  city of the CCP2 test
       Sensitivity  Specifi  city
Patient group  n  Anti-CCP2(+)   (%)   (%)
RA total  17,359  12,431  71.6 
 Early  4,379  2,677  61.1 
 Established  12,980  9,754  75.1 
Controls 20,222  960  4.7  95.3
 Non-RA  15,461  911  5.9  94.1
 Healthy  4,761  49  1.0  99.0
The cumulative sensitivity and specifi  city of the CCP2 test is based on the results 
of 154 independent studies published between 2002 and June 2009. Separation 
into early and established rheumatoid arthritis (RA) was adapted from the 
original studies.
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citrullinated protein antibody tests
In the past 3 years about 25 articles have appeared in 
which performances of diﬀ   erent ACPA tests were 
compared. Only nine of these studies, however, followed 
the essential principle that any such comparisons can 
only be made when the test results are properly stratiﬁ  ed. 
Stratiﬁ   cation means that sensitivity values have to be 
calculated at a predeﬁ  ned  speciﬁ   city (mostly 98% or 
more) using the same cohort of RA patients and disease 
control sera. Th   e chosen speciﬁ  city should be as high as 
possible without compromising essential sensitivity, and 
thus the overall diagnostic eﬃ   ciency. Another important 
point is the cohort of patients selected for such studies.
Th   e main advantage of ACPA lies in their proven ability 
to predict the development of RA and their potential use 
as a criterion for RA even at baseline [22]. Th  e ideal 
cohort to evaluate the clinical value of ACPA tests is 
therefore the mixed population of patients visiting an 
early arthritis clinic where some patients eventually will 
develop RA [6]. Th  e use of a cohort of established RA 
patients with longstanding disease is clearly less useful. 
In the studies reviewed in the present article, all sorts of 
RA patient cohorts and control groups have been used, 
and this, at least in part, explains some of the diﬀ  erences 
in sensitivity and speciﬁ   city of ACPA tests between 
diﬀ  erent studies.
The tests
It is primarily the antigen (substrate) that decides how 
speciﬁ  c or sensitive a test will be. In 2002 the CCP2 test 
was launched, and this test is still the golden standard 
and most frequently used test in clinical practice. Table 1 
presents the accumulated data from 154 publications 
using the CCP2 test.
Th  ere are at least six tests available using the CCP2 
peptides as the antigen (supplied by Axis-Shield, Euro-
Diagnostica, Euroimmun, Inova, Phadia, and Abbott). 
Despite using the same set of CCP2 peptides, these assays 
tend to show small diﬀ  erences in their diagnostic proﬁ  les 
[23,24]. Th  e main reason for these diﬀ   erences is that 
although the antigen is the same, the solid support 
materials might be diﬀ  erent – and the added variables 
(conjugate, buﬀ  ers, incubation time, and so forth) are 
also diﬀ  erent, and these may also contribute to the small 
diﬀ  erences reported.
Aside from the CCP2 test, several other ACPA tests 
using diﬀ  erent substrates have more recently been made 
commercially available. Some of these newer tests have 
rarely been used in published studies and are therefore 
not included in our calculations.
Assays that have been used in published data include a 
test based on in vitro citrullinated mutated human 
vimentin as antigen (MCV; Orgentec, Mainz, Germany), 
the Inova CCP3 test (cyclic citrullinated peptides) and its 
variant Inova CCP3.1 (Inova, San Diego, CA, USA), the 
Genesis  citrullinated recombinant rat ﬁ  laggrin  (cFil; 
Genesis, Littleport, UK), the Aesku citrullinated IgG 
peptide (cIgG; Aesku, Wendelsheim, Germany) and the 
Astra citrullinated Epstein–Barr virus nuclear antigen-
derived peptide (Astra, Hamburg, Germany). In 
publications in which (some of) these tests are compared, 
the RF-IgM test is also often included. Th   e RF tests are 
mostly used without a clinically useful cut-oﬀ   point based 
on predeﬁ  ned  speciﬁ   city, however, and thus true 
comparisons of results obtained with this test in diﬀ  erent 
studies are not possible.
Diagnostic performance of anti-citrullinated 
protein antibody tests
Th   e data extracted from recent literature and tabulated in 
Tables 2 and 3 show that the CCP2 test still performs best 
when compared with other ACPA tests. Comparison 
with the classical IgM-RF test conﬁ  rms previous reports 
that the CCP2 test has a superior speciﬁ   city and, in 
stratiﬁ   ed studies, a much higher sensitivity (Table  2). 
Recent data from Van der Linden and coworkers [17] – 
who showed that the rate of joint destruction in RA was 
not aﬀ  ected by the presence or absence of IgM RF, but 
rather by the presence or absence of ACPA – corroborate 
the idea that ACPA positivity should be included as a 
criterion for the diagnosis of RA in clinical studies [25]. 
Th   ese authors also advocated the inclusion of ACPA into 
any revision of the current ACR criteria for RA. 
Interestingly, the European League against Rheumatism 
has already recommended that the measurement of anti-
CCP should be considered in all new cases of RA [26], 
and at the latest ACR meeting in Philadelphia an ACR/
European League against Rheumatism panel of specialists 
included ACPA testing in the New Rheumatoid Arthritis 
Criteria.
Several studies have addressed the diagnostic perfor-
mance of the MCV assay. In stratiﬁ  ed studies this test 
shows a lower sensitivity (see Table 2), and in nonstratiﬁ  ed 
studies a lower speciﬁ  city, than the CCP2 test [27-30]. A 
similar conclusion was reached in a recent review on the 
diagnostic and prognostic properties of the MCV assay 
[31]. Th   ere are a few reports indicating that anti-MCV is 
present in a signiﬁ   cant number of anti-CCP(–) sera 
[21,32-34], and this subgroup of patients appears to have 
a higher rate of radiographic destruction than sero-
negative patients. Anti-MCV positivity therefore seems 
to indicate poor radiographic prognosis in a larger group 
of RA patients than anti-CCP positivity does [34]. Data 
from the study of Van der Linden and collaborators, 
however, indicate that the presence of anti-MCV 
antibody with negative anti-CCP does not strongly aﬀ  ect 
the level of joint damage in RA [17]. It is clear that further 
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characterized cohorts is needed. It would also be useful 
to introduce a control mutated vimentin antigen (not 
citrullinated) in order to test whether this CCP-negative 
population of anti-MCV antibody is directed to the 
vimentin protein or to the citrulline moiety of mutated 
vimentin [9,35].
Only the CCP3 test appears in some studies to be 
comparable with the CCP2 test [36-38], although in the 
majority of published studies the CCP3 test shows a 
somewhat lower speciﬁ  city and/or sensitivity [23,24,39-43]. 
Based upon the combined results of these studies it can 
be concluded that the CCP3 test has no apparent 
diagnostic advantage compared with the CCP2 test. 
Inova has also recently introduced the CCP 3.1 test, 
which additionally includes measurement of IgA anti-
bodies. In general this test does not appear to be better 
than the CCP3 test [23,41], and the CP 3.1 test would 
Table 2. Comparison of the sensitivity of various ACPA and RF tests at stratifi  ed specifi  city
 Number  of  Stratifi  ed                    Sensitivity at stratifi  ed specifi  city (%)
 patients  specifi  city
Reference (RA/control)  (%)  CCP2  CCP3  MCVa Other  RF
Bizzaro and colleagues [23]  100/202  98.5  64 to 74b,c,d,e,f 67g,h  62  41 to 47i,j,k 17
Coenen and colleagues [44];   102/196  95.0  76.2 to 77.0b,d,e 75.5g 65.7  69.3j ND
Bossuyt, personal communication
Damjanovska and colleagues [50];   566/351  93.4  56.9e 56.2h 52.5 ND  ND
Thabet, personal communication
Dejaco and colleagues [51]  164/303  98.7  70.1d ND 53.7  ND  ND
Innala and colleagues [41]  210/102  98.0  80.4c  78.5 to 79.0g,h 69.0  ND  ND
Mutlu and colleagues [37]  93/83  98.8  57.0 to 60.2l,f 60.2g 29 ND 48.4
Soos and colleagues [52]  119/118  95  74.8  ND  69.7  ND  33.6
Vander Cruyssen and colleagues [53]  272/463  98.5  67.4 to 68.0e  ND  ND  ND  16.3 to 24.4
Vander Cruyssen and colleagues [42] (early arthritis)  92/463  98.7  61.6 to 67.4d,e 58.1g ND ND  ND
Vander Cruyssen and colleagues [42] (established RA)  180/463  98.7  65.2 to 77.4d,e 67.1g ND ND  ND
Average    97.3 69.2 66.1 57.4    29.9
Control groups are not identical. ACPA, anti-citrullinated protein antibodies; ND, not determined; RA, rheumatoid arthritis; RF, rheumatoid factor. aAnti-MCV (Orgentec, 
Mainz, Germany). bCCP IgG (Euroimmun, Lubeck, Germany). cDiastat anti-CCP (Axis-Shield, Dundee, UK). dEliA CCP (Phadia, Freiburg, Germany). eImmunoscan-RA 
Mark 2 (Euro-Diagnostica, Arnhem, the Netherlands). fQuanta Lite CCP IgG (Inova, San Diego, CA, USA). gQuanta Lite CCP 3.0 IgG (Inova). hQuanta Lite CCP 3.1 IgG-
IgA (Inova). iCPA (Genesis, Littleport, UK). jAeskulisa RA CP-Detect (Aesku, Wendelsheim, Germany). kVCP IgG (Astra, Hamburg, Germany). lAxSYM anti-CCP (Abbott, 
Princeton, NJ, USA).
Table 3. Comparison of ACPA and RF tests in terms of positive and negative predictive values
  Number of                           CCP2                              CCP3                           MCV                            RF
 patients
Reference  (RA/control)  PPV (%)  NPV (%)  PPV (%)  NPV (%)  PPV (%)  NPV (%)  PPV (%)  NPV (%)
Luis Caro-Oleas and colleagues [54]  124/158  95.2  73.1  92.3  70.5      90.9  73.6
Coenen and colleagues [44]d  133/165  89.7 to 91.4a  87.1 to 89.1a  76.7 88.2 80.0 87.2   
Correia and colleagues [39]  86/90  92.6 to 96.7b 72.9 to 78.7b 91.9 to 94.9b 74.4 to 74.6b     80.3  72.4
Dos Anjos and colleagues [40]  70/88  91.7  84.7  90.6  87.2       
Liu and colleagues [33]  170/136  95.5  66.8      93.7  77.4  82.0  69.9
Lutteri and colleagues [24]  120/170  87.7 to 96.2c  76.6 to 78.3c  92.6  78.1    77.9  79.5
Sghiri and colleagues [29]  170/309  91.1  86.3      66.0  84.7  58.6  79.9
Soos and colleagues [52]  119/118  97.6  74.4      90.0  78.8  80.2  74.0
Ursum and colleagues [48]  123/39  95.8        96.1     
Van der Linden and colleagues [17]  201/424  67.1  79.0  64.0  80.0  56.3  79.2  61.7  77.8
Average    91.2 78.4 84.9 79.8 80.4 81.5 75.9 75.3
Control groups are not identical. ACPA, anti-citrullinated protein antibodies; MCV, mutated citrullinated vimentin; NPV, negative predictive value; PPV, positive 
predictive value; RA, rheumatoid arthritis; RF, rheumatoid factor. aThree CCP2 tests used. bTwo CCP2 tests and two cut-off   values used. cSix CCP2 tests used. dCoenen 
and collaborators also used the citrullinated fi  laggrin test (CPA; Genesis, Littleport, UK): PPV, 85.5; NPV, 85.6.
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setup.
Citrullinated peptide antigens have also been derived 
from proteins like Epstein–Barr virus nuclear antigen 
(Astra) and IgG (Aesku). Th  e tests with these peptides 
were included in the stratiﬁ   ed study of Bizzaro and 
collaborators [23], but scored rather low in sensitivity 
(Aesku 44%, Astra 47%). In a single study, the Genesis 
cFil test shows a positive predictive value that is lower 
than that of the CCP2 test, but higher than the positive 
predictive value of the CCP3 and MCV tests [44]. Finally, 
Lutteri and coworkers also measured the diagnostic 
abilities of a new test using synthetic citrullinated 
peptides (RA/CP; Triturus, Bad Kreuznach, Germany). 
Th  e speciﬁ  city, sensitivity, positive predictive value and 
negative predictive value of this test were all much lower 
than those of the CCP2 and CCP3 tests [24].
What test is best for the clinician?
As outlined above, ACPA are not only important pre-
dictors of RA development but are also among the most 
potent predictors of the outcome of RA, as measured by 
the rate of radiographic joint destruction. Th  ere are at 
least four clinically important reasons to perform and 
compare ACPA tests: the ability to conﬁ  rm or predict the 
development of RA with the highest reliability; the ability 
to predict radiographic progression; the ability to predict 
remission; and the ability to predict response to anti-
TNFα treatment.
First, from Tables 1 to 3 it is clear that although most 
ACPA tests are perfectly able to predict or conﬁ  rm a 
diagnosis of RA, none of the tests has a better diagnostic 
record than the CCP2 test. In addition, it was reported 
recently that the positive predictive value for predicting 
progression from undiﬀ   erentiated arthritis to RA was 
highest for CCP2 (67.1%). Combinations of two or more 
ACPA tests appear to give no additive value [17]. A 
somewhat diﬀ  erent situation may exist for the additional 
testing of RF, since RF testing may carry additional 
clinical value beyond testing for anti-CCP alone [45]. It 
should be noted that RF positivity still is a criterion for 
RA, and that RF-positive/anti-CCP(–) RA patients 
display diﬀ  erent environmental risk factors than those 
that are only anti-CCP(+) [3].
Second, a positive test for anti-CCP2, anti-CCP3, or 
anti-MCV was associated with a higher Sharp/van der 
Heijde score at all time points except baseline and was 
also associated with a higher rate of joint destruction 
over a period of 7 years [17]. Th  ere was no diﬀ  erence 
between these tests with regard to their ability to predict 
radiographic progression. Th  e use of a second or third 
autoantibody test did not increase the predictive 
accuracy for the rate of joint destruction [17]. Similar 
results were reported by Dejaco and colleagues [36], 
Majka and colleagues [46], and Syversen and colleagues 
[47]. It is also interesting to note that not only in the 
presence of ACPA, but also in the absence of these 
antibodies, RF did not signiﬁ   cantly correlate with 
increased rates of joint destruction. Th  is indicates that 
RF, in contrast to ACPA, does not by itself contribute to 
disease progression. In some studies MCV was reported 
to have a somewhat higher sensitivity (mostly accom-
panied by a lower speciﬁ  city) than CCP2 (for example 
[27,32-34]). Th   ese studies, however, also showed that the 
rate of joint destruction in MCV-positive/CCP(–) 
patients was comparable with that in patients lacking 
ACPA, indicating that the presence of anti-MCV anti-
body alone does not aﬀ  ect the level of joint damage in RA 
[17,33,48].
Th   ird, the test’s ability to predict the likelihood of not 
achieving sustained disease-modifying antirheumatic 
drug-free remission was highest (11.6%) for anti-CCP2 
and varied between 4.7 and 6.0% for anti-CCP3, anti-
MCV and RF [17]. Again, performing two ACPA tests 
had no additional value compared with the anti-CCP2 
test alone. It is clear, however, that we need more data on 
this aspect of ACPA testing.
Finally, treatment of RA is mostly assumed to combat 
important disease mechanisms and thus lower the 
inﬂ  ammation. As a consequence one might also expect a 
reduction of the activation of autoreactive B cells 
followed by reduced ACPA levels, which would allow 
monitoring of the eﬀ   ect of treatment. In the initial 
studies no signiﬁ  cant eﬀ  ect of inﬂ  iximab on anti-CCP 
levels was observed (reviewed by Zendman and collabor-
ators [49]). Also in later studies neither anti-CCP3 nor 
anti-CCP2 levels were found to be inﬂ  uenced by TNFα 
blocking agents, and the test results failed to predict 
responses to anti-TNFα treatment [36]. A possible reason 
for these observations may be that although the 
inﬂ   ammation may decrease, the citrullinated antigens 
(and consequently the production of autoantibodies and 
immune complexes) are still there, and this is reﬂ  ected in 
the antibody levels (see [1]). In other studies, however, 
signiﬁ  cant decreases of anti-CCP2 and anti-MCV titers 
at 18 months and/or 24 months of inﬂ  iximab treatment 
have been reported [27]. At the moment we have to 
conclude that none of the available ACPA tests 
unequivocally shows the ability to predict response to 
treatment.
Perspectives
Reference serum
In most of the commercially available tests the cut-oﬀ   
values used to deﬁ  ne a positive result vary signiﬁ  cantly, 
even when the antigenic substrate is provided by the 
same manufacturer [23]. Th  ere is therefore an urgent 
need for reference material that can help investigators to 
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available tests. Th   e use of International Units, based on 
the reactivity of a reference serum or antibody, will 
hopefully help laboratory experts and clinicians to decide 
which serum is ACPA-positive and which is not.
At the request of the Committee for the Standardization 
of Autoantibodies in Rheumatic and Related Diseases, 
the Center for Disease Control and Prevention (Atlanta, 
GA, USA) has prepared a lyophilized reference material, 
obtained from an RF-positive and ACPA-positive patient, 
which is available on request as an international ACPA 
reference reagent.  Th  is reference reagent has already 
been tested by some laboratories using several commer-
cial tests, and was found to improve considerably the 
comparison of quantitative results between diﬀ  erent 
commercial tests (N Bizzaro, personal communication). 
Th   e reference serum has also been tested by laboratories 
of several members of the Committee for the Standard-
ization of Autoantibodies in Rheumatic and Related 
Diseases, using the same substrate and using kits 
commer  cially available in Europe, and is now available at 
the Center for Disease Control and Prevention for the 
scientiﬁ   c community (PL Meroni, personal 
communi cation).
Universal serum collection
A second important development that will help to 
compare the speciﬁ   city and sensitivity of ACPA (and 
other) tests is the initiative of the European AutoCure 
consortium to generate a large depository of sera from 
patients with RA and other rheumatic diseases that will 
become available for comparative diagnostic studies. Th  e 
use of a universal set of RA patients and control sera will 
allow a direct comparison of the diagnostic performance 
of current tests and those yet to be developed.
Potential test improvements
From several recent studies it became clear that a positive 
reaction in an ACPA test for non-RA sera is frequently 
due to the presence of antibodies that recognize the 
target molecule in a noncitrulline-dependent fashion, 
because the same molecule containing arginine instead of 
citrulline was bound by the antibodies at least as eﬃ   ci-
ently as the citrullinated antigen [9,35]. Th  is  observation 
indicates that the inclusion of a noncitrullinated control 
antigen in the test is likely to improve the speciﬁ  city of 
the test for RA. Currently it is not clear whether the 
manufacturers of ACPA tests are considering such a 
modiﬁ  cation of the test.
Finally, since each of the target molecules used for 
ACPA detection might have its speciﬁ   c utility in the 
identiﬁ  cation of a particular subset of RA patients, the 
development of multiplex tests combining all of these 
target molecules in a single analysis may be a signiﬁ  cant 
step forward in the detailed analysis of autoantibody 
reactivities in sera of this heterogeneous disease. Several 
experimental platforms can be envisaged to achieve this, 
including ﬂ  uorescent secondary antibody-based micro-
arrays, imaging surface plasmon resonance-based micro-
arrays and Luminex addressable beads or nanotechnology-
based systems.
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